622 related articles for article (PubMed ID: 24061039)
1. Gastric cancer-molecular and clinical dimensions.
Wadhwa R; Song S; Lee JS; Yao Y; Wei Q; Ajani JA
Nat Rev Clin Oncol; 2013 Nov; 10(11):643-55. PubMed ID: 24061039
[TBL] [Abstract][Full Text] [Related]
2. Personalised Treatment in Gastric Cancer: Myth or Reality?
Tarazona N; Gambardella V; Huerta M; Roselló S; Cervantes A
Curr Oncol Rep; 2016 Jul; 18(7):41. PubMed ID: 27215435
[TBL] [Abstract][Full Text] [Related]
3. Molecularly targeted therapies in unresectable-metastatic gastric cancer: a systematic review.
Zagouri F; Papadimitriou CA; Dimopoulos MA; Pectasides D
Cancer Treat Rev; 2011 Dec; 37(8):599-610. PubMed ID: 21676549
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy.
Patrad E; Khalighfard S; Amiriani T; Khori V; Alizadeh AM
Cell Oncol (Dordr); 2022 Dec; 45(6):1073-1117. PubMed ID: 36149600
[TBL] [Abstract][Full Text] [Related]
5. Targeting the MET Pathway in Gastric and Oesophageal Cancers: Refining the Optimal Approach.
Lee J; Tran P; Klempner SJ
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):e35-44. PubMed ID: 26880063
[TBL] [Abstract][Full Text] [Related]
6. Proteomic and metabolic prediction of response to therapy in gastric cancer.
Aichler M; Luber B; Lordick F; Walch A
World J Gastroenterol; 2014 Oct; 20(38):13648-57. PubMed ID: 25320503
[TBL] [Abstract][Full Text] [Related]
7. Recent updates of precision therapy for gastric cancer: Towards optimal tailored management.
Joo MK; Park JJ; Chun HJ
World J Gastroenterol; 2016 May; 22(19):4638-50. PubMed ID: 27217696
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy for gastric cancer--current status.
Kulig J; Kołodziejczyk P; Kulig P; Legutko J
J Oncol Pharm Pract; 2013 Mar; 19(1):75-81. PubMed ID: 22711713
[TBL] [Abstract][Full Text] [Related]
9. Current advances in targeted therapies for metastatic gastric cancer: improving patient care.
Aguiar PN; Muniz TP; Miranda RR; Tadokoro H; Forones NM; Monteiro ID; Castelo-Branco P; Janjigian YY; De Mello RA
Future Oncol; 2016 Mar; 12(6):839-54. PubMed ID: 26838766
[TBL] [Abstract][Full Text] [Related]
10. Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.
Ali SM; Sanford EM; Klempner SJ; Rubinson DA; Wang K; Palma NA; Chmielecki J; Yelensky R; Palmer GA; Morosini D; Lipson D; Catenacci DV; Braiteh F; Erlich R; Stephens PJ; Ross JS; Ou SH; Miller VA
Oncologist; 2015 May; 20(5):499-507. PubMed ID: 25882375
[TBL] [Abstract][Full Text] [Related]
11. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response.
Wang R; Song S; Harada K; Ghazanfari Amlashi F; Badgwell B; Pizzi MP; Xu Y; Zhao W; Dong X; Jin J; Wang Y; Scott A; Ma L; Huo L; Vicente D; Blum Murphy M; Shanbhag N; Tatlonghari G; Thomas I; Rogers J; Kobayashi M; Vykoukal J; Estrella JS; Roy-Chowdhuri S; Han G; Zhang S; Mao X; Song X; Zhang J; Gu J; Johnson RL; Calin GA; Peng G; Lee JS; Hanash SM; Futreal A; Wang Z; Wang L; Ajani JA
Gut; 2020 Jan; 69(1):18-31. PubMed ID: 31171626
[TBL] [Abstract][Full Text] [Related]
12. Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers.
Cho SY; Park JW; Liu Y; Park YS; Kim JH; Yang H; Um H; Ko WR; Lee BI; Kwon SY; Ryu SW; Kwon CH; Park DY; Lee JH; Lee SI; Song KS; Hur H; Han SU; Chang H; Kim SJ; Kim BS; Yook JH; Yoo MW; Kim BS; Lee IS; Kook MC; Thiessen N; He A; Stewart C; Dunford A; Kim J; Shih J; Saksena G; Cherniack AD; Schumacher S; Weiner AT; Rosenberg M; Getz G; Yang EG; Ryu MH; Bass AJ; Kim HK
Gastroenterology; 2017 Aug; 153(2):536-549.e26. PubMed ID: 28522256
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy in advanced gastric carcinoma: the future is beginning.
Schinzari G; Cassano A; Orlandi A; Basso M; Barone C
Curr Med Chem; 2014; 21(8):1026-38. PubMed ID: 24304282
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?
Pasini F; Fraccon AP; Modena Y; Bencivenga M; Giacopuzzi S; La Russa F; Gusella M; de Manzoni G
Gastric Cancer; 2017 Jan; 20(1):31-42. PubMed ID: 27568322
[TBL] [Abstract][Full Text] [Related]
15. The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.
Aprile G; Giampieri R; Bonotto M; Bittoni A; Ongaro E; Cardellino GG; Graziano F; Giuliani F; Fasola G; Cascinu S; Scartozzi M
Expert Opin Investig Drugs; 2014 Jul; 23(7):925-42. PubMed ID: 24806575
[TBL] [Abstract][Full Text] [Related]
16. mTOR as a therapeutic target in patients with gastric cancer.
Al-Batran SE; Ducreux M; Ohtsu A
Int J Cancer; 2012 Feb; 130(3):491-6. PubMed ID: 21898386
[TBL] [Abstract][Full Text] [Related]
17. Molecular Mechanism of Resistance to Chemotherapy in Gastric Cancers, the Role of Autophagy.
Spirina LV; Avgustinovich AV; Afanas'ev SG; Cheremisina OV; Volkov MY; Choynzonov EL; Gorbunov AK; Usynin EA
Curr Drug Targets; 2020; 21(7):713-721. PubMed ID: 31775598
[TBL] [Abstract][Full Text] [Related]
18. Update on metastatic gastric and esophageal cancers.
Shah MA
J Clin Oncol; 2015 Jun; 33(16):1760-9. PubMed ID: 25918288
[TBL] [Abstract][Full Text] [Related]
19. Novel targeted agents for gastric cancer.
Liu L; Wu N; Li J
J Hematol Oncol; 2012 Jun; 5():31. PubMed ID: 22709792
[TBL] [Abstract][Full Text] [Related]
20. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
